Jane Street’s Acer Therapeutics Inc ACER Stock Holding History

Jane Street’s Portfolio ACER Stock Details ACER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-18,574	Closed	-$64K	–	8156
2020 Q2	$64K	Buy	+18,574	New	+$52.4K	﹤0.01%	6819
2019 Q3	–	Sell	-12,484	Closed	-$49K	–	5939
2019 Q2	$49K	Buy	+12,484	New	+$238K	﹤0.01%	4958
2015 Q3	–	Sell	-150	Closed	-$6K	–	4301
2015 Q2	$6K	Buy	+150	New	+$5.76K	﹤0.01%	3571

Other funds holding ACER

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jane Street's ACER Position: Q3 2020 in Review

Jane Street sold out of Acer Therapeutics Inc (ACER) in Q3 2020, closing a stake of 18,574 shares — an estimated $64K sold.

Jane Street first reported a position in ACER in Q2 2015 and held it in 3 quarters. The position peaked at $64K in Q2 2020. 27 funds tracked by Wall St. Rank hold ACER as of Q3 2020.

Jane Street reported no remaining Acer Therapeutics Inc position as of Q3 2020 after selling out during the quarter.
Jane Street sold 18,574 Acer Therapeutics Inc shares in Q3 2020, an estimated $64K.
Jane Street first reported a position in Acer Therapeutics Inc in Q2 2015 and held it in 3 quarters.
Jane Street's Acer Therapeutics Inc position peaked at $64K in Q2 2020.
27 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q3 2020.

Based on Jane Street's 13F filing for Q3 2020, filed 17 Nov 2020.